An open trial of lurasidone as an acute and maintenance adjunctive treatment for outpatients with treatment-resistant bipolar disorder

Journal of Clinical Psychopharmacology

Volumn 36, Issue 1, 2016, Pages 88-89

  Schaffer, Charles B ^a   Schaffer, Linda C ^b   Nordahl, Thomas E ^a   Stark, Nicole M ^b   Gohring, Caroline E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Sutter Community Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LURASIDONE; SEROTONIN 7 RECEPTOR; NEUROLEPTIC AGENT;

ADULT; AGITATION; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; BIPOLAR DISORDER; DISEASE SEVERITY; DRUG INDICATION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DSM-IV; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; IRRITABILITY; LETTER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; TREATMENT RESISTANT BIPOLAR DISORDER; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; AGED; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; OUTPATIENT; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HUMANS; LURASIDONE HYDROCHLORIDE; MALE; MIDDLE AGED; OUTPATIENTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84952975866     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000450     Document Type: Letter

References (9)

1. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:1911-1922.
2. Loebel A, Oucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:160-168.
3. Loebel A, Oucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:169-177.
4. Ketter TA, Sarma K, Silva R, et al. Lurasidone in bipolar I depression: a 24-week, open-label extension study. Poster presented at US Psychiatric and Mental Health Congress. September 20-23, 2014, Orlando, FL.
5. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010; 334:171-181.
6. Lincoln J, Aveekshit T. Lurasidone for schizophrenia. Curr Psychiatr. 2011;10:67-70.
7. Spearing M, Post R, Leverich G, et al. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73:159-171.
8. SanfordM, Dhillon S. Lurasidone: a reviewof its use in adult patients with bipolar I depression. CNS Drugs. 2015;29:253-263.
9. Horisawa T, Ishiyama T, OnoM, et al. Binding of lurasidone, a novel antipsychotic, to rat 5-HT7 receptor: Analysis by [3H]SB-269970 autoradiography. Prog Neuropsychopharmacol Biol Psychiatry. 2013;40:132-137.